Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?

British journal of cancer - 20 Nov 2012

Paliga A, Onerheim R, Gologan A, Chong G, Spatz A, Niazi T, Garant A, Macheto D, Alcindor T, Vuong T

Abstract excerpt

BACKGROUND: There is a growing appreciation for radio-sensitiser use in multi-modal cancer treatment models. Squamous cell anal carcinoma (SCAC) is a rare gastrointestinal tumour traditionally treated with concurrent chemotherapy and radiation. Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, has demonstrated significant efficacy when combined with radiation in squamous cell carcinoma of the head...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anus Neoplasms
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Head and Neck Neoplasms

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 23093229
DOI: 10.1038/bjc.2012.479
PMCID: PMC3504953

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?PMID 23093229Read ↗

EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.Semantic proximity Read ↗

K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?Semantic proximity Read ↗

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).Semantic proximity Read ↗

Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.Semantic proximity Read ↗

Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.Semantic proximity Read ↗

Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention.Semantic proximity Read ↗

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).Semantic proximity Read ↗

p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy.Semantic proximity Read ↗

KRAS and BRAF mutations in anal carcinoma.Semantic proximity Read ↗

EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas.Semantic proximity Read ↗

Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab.Semantic proximity Read ↗

Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.